PT  - JOURNAL ARTICLE
AU  - Kumar, Pradeep
AU  - Rai, Vandana
TI  - “Catechol-O-methyltransferase gene Val158Met polymorphism and prostate cancersusceptibility”
AID  - 10.1101/2020.04.16.20067736
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.16.20067736
4099  - http://medrxiv.org/content/early/2020/04/19/2020.04.16.20067736.short
4100  - http://medrxiv.org/content/early/2020/04/19/2020.04.16.20067736.full
AB  - Prostate cancer is one of the most common and a serious malignancy of males and it is well reported that estrogen plays a pivotal role in prostate carcinogenesis. Catechol-O - methyltransferase (COMT) catalyzes the inactivation of estrogens. Several studies have investigated the association of COMT gene Val158Metpolymorphism with prostate cancer, but results were inconsistent and inconclusive. Hence, to assess this association, we performed a meta-analysis of all published case-control studies. Pubmed, Springer link, Google Scholar, Elsevier and Springer link databases were searched for case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) was used as association measure. Statistical analysis was performed with the software program MIX and MetaAnalyst. In the current meta-analysis, 11 case control studies with 3381 prostate cancer cases and 3,276 healthy controls were considered. The results indicated no significant association between COMT Val158Met polymorphism and prostate cancer risk using allele contrast, co-dominant and homozygote models (allele contrast: OR= 0.92; 95% CI 0.85 to 0.98=; p= 0.02; co-dominant: OR=0.81; 95% CI= 0.85 to1.07; p= 0.46; homozygote: OR= 0.81; 95% CI= 0.70 to 0.95, p= 0.008), but showed significant association with dominant and recessive models (dominant: OR 1.18=; 95% CI= 1.03 to1.34; p= 0.01; recessive: OR= 1.54; 95% CI= 1.1 to 2.07; p = 0.003). In subgroup analysis meta-analysis using recessive genetic model showed significant association between COMT Val 158Met polymorphism and prostate cancer risk in both Asian and Caucasian populations. In conclusion, results of present meta-analysis supports that the COMT Val158Met polymorphism is risk factor for prostate cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript.COMTCatechol-O-methyltransferaseVal158MetValine158Methionine;OROdd ratioCIConfidence interval